Related Experiment Video

Updated: May 18, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma

Yuji Shimura1, Junya Kuroda, Masaki Ri

  • 1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Molecular Cancer Therapeutics
|September 27, 2012
PubMed

Insights

Targeting RSK2(Ser227) shows promise for treating multiple myeloma. Inhibiting this protein induces apoptosis and overcomes resistance to current therapies, offering new hope for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Multiple myeloma is a heterogeneous plasma cell neoplasm that remains incurable despite advances in targeted therapies.
  • Identifying novel therapeutic targets converging cell-survival pathways is crucial for developing new treatment strategies.
  • Ribosomal S6 kinase 2 (RSK2) is a key mediator in the ERK1/2 signaling pathway, crucial for cancer cell survival and proliferation.

Purpose of the Study:

  • To investigate RSK2(Ser227) as a potential therapeutic target in multiple myeloma.
  • To evaluate the effects of RSK2(Ser227) inhibition on myeloma cell proliferation and survival.
  • To assess the efficacy of RSK2(Ser227) inhibition in combination with existing multiple myeloma therapies.

Main Methods:

  • Analysis of RSK2(Ser227) activation in multiple myeloma cell lines and patient samples.
  • Chemical inhibition of RSK2(Ser227) using BI-D1870 and gene knockdown of RSK2.
  • Assessment of apoptosis induction, cell proliferation, and downstream signaling pathway modulation (c-MYC, cyclin D, p21, MCL1).
  • Evaluation of combination effects with lenalidomide, bortezomib, and other targeted agents.

Main Results:

  • RSK2(Ser227) was found to be activated in all examined multiple myeloma cell lines and most patient samples, irrespective of cytogenetic abnormalities.
  • Inhibition of RSK2(Ser227) by BI-D1870 or RSK2 knockdown led to significant myeloma cell proliferation inhibition via apoptosis induction.
  • RSK2(Ser227) inhibition downregulated key survival proteins including c-MYC, cyclin D, p21(WAF1/CIP1), and MCL1.
  • RSK2(Ser227) inhibition restored lenalidomide efficacy, showed no cross-resistance with bortezomib, and demonstrated synergistic effects with other targeted therapies.

Conclusions:

  • RSK2(Ser227) is a consistently activated and druggable target in multiple myeloma.
  • Targeting RSK2(Ser227) induces myeloma cell death and overcomes resistance mechanisms, including IL-6 protection.
  • RSK2(Ser227) inhibition represents a promising therapeutic strategy for both newly diagnosed and refractory multiple myeloma patients.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...